4.5 Article

Reactive Oxygen Species Signaling Promotes Hypoxia-Inducible Factor 1 α Stabilization in Sonic Hedgehog-Driven Cerebellar Progenitor Cell Proliferation

Journal

MOLECULAR AND CELLULAR BIOLOGY
Volume 39, Issue 8, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00268-18

Keywords

Sonic Hedgehog; hypoxia-inducible factor 1a; medulloblastoma; reactive oxygen species; stem cells

Funding

  1. NINDS [R01NS061070]
  2. NCI Winship Cancer Institute P30 Center grant [CA138292]

Ask authors/readers for more resources

Cerebellar development is a highly regulated process involving numerous factors acting with high specificity, both temporally and by location. Part of this process involves extensive proliferation of cerebellar granule neuron precursors (CGNPs) induced by Sonic Hedgehog (SHH) signaling, but downstream effectors of mitogenic signaling are still being elucidated. Using primary CGNP cultures, a well-established model for SHH-driven proliferation, we show that SHH-treated CGNPs feature high levels of hypoxia-inducible factor l alpha (HIF1 alpha), which is known to promote glycolysis, stemness, and angiogenesis. In CGNPs cultured under normoxic conditions, HIFI alpha is posttranslationally stabilized in a manner dependent upon reactive oxygen species (ROS) and NADPH oxidase (NOX), both of which are also upregulated in these cells. Inhibition of NOX activity resulted in HIFI a destabilization and reduced levels of cyclin D2, a marker of CGNP proliferation. As CGNPs are the putative cells of origin for the SHH subtype of medulloblastoma and aberrant SHH signaling is implicated in other neoplasms, these studies may also have future relevance in the context of cancer. Taken together, our findings suggest that a better understanding of nonhypoxic HIFla stabilization through NOX-induced ROS generation can provide insights into normal cell proliferation in cerebellar development and SHH-driven cell proliferation in cancers with aberrant SHH signaling.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Clinical Neurology

Clinical Level of Evidence Presented at the Cervical Spine Research Society (CSRS) Annual Meeting Over 10 Years (2008-2017) A Systematic Review

Nicholas W. Eyrich, Daniel Liesman, Nicole A. Pescatore, Ilyas S. Aleem

SPINE (2020)

Editorial Material Surgery

COVID-19 & the Residency Match The Added Importance of Mentoring

Bridger M. Rodoni, Nicholas W. Eyrich, David P. Fessell

ANNALS OF SURGERY (2020)

Article Urology & Nephrology

Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice

Amir H. Lebastchi, Christopher M. Russell, Yashar S. Niknafs, Nicholas W. Eyrich, Zoey Chopra, Rachel Botbyl, Rana Kabeer, Takahiro Osawa, Javed Siddiqui, Rabia Siddiqui, Matthew S. Davenport, Rohit Mehra, Scott A. Tomlins, Lakshimi P. Kunju, Arul M. Chinnaiyan, John T. Wei, Jeffrey J. Tosoian, Todd M. Morgan

UROLOGY (2020)

Article Urology & Nephrology

Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach

Jeffrey J. Tosoian, Bruce J. Trock, Todd M. Morgan, Simpa S. Salami, Scott A. Tomlins, Daniel E. Spratt, Javed Siddiqui, Lakshmi P. Kunju, Rachel Botbyl, Zoey Chopra, Balaji Pandian, Nicholas W. Eyrich, Gary Longton, Yingye Zheng, Ganesh S. Palapattu, John T. Wei, Yashar S. Niknafs, Arul M. Chinnaiyan

Summary: The MyProstateScore test has high sensitivity and negative predictive value for ruling out clinically significant prostate cancer in men. It can reduce unnecessary biopsies with low missed detection rates, providing a cost-effective and less invasive approach after initial prostate specific antigen screening.

JOURNAL OF UROLOGY (2021)

Editorial Material Surgery

Bridging the Digital Divide to Avoid Leaving the Most Vulnerable Behind

Nicholas W. Eyrich, Juan J. Andino, David P. Fessell

Summary: The Viewpoint advocates for the continuation and enhancement of telehealth practices, with a focus on advancing techniques to ensure accessibility for individuals with limited access to internet and smartphone technologies.

JAMA SURGERY (2021)

Review Andrology

Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions

Nicholas W. Eyrich, Todd M. Morgan, Jeffrey J. Tosoian

Summary: The use of serum PSA testing for early detection of prostate cancer can reduce cancer-specific mortality, but carries substantial risks including frequent unnecessary prostate biopsies and overdetection of non-aggressive cancers. Clinical validation data for biomarkers with improved specificity for GG >= 2 cancer have been proposed, aiming to improve screening accuracy for clinically significant cancers.

TRANSLATIONAL ANDROLOGY AND UROLOGY (2021)

Editorial Material Oncology

Reporting of Racial Health Disparities Research: Are We Making Progress?

Randy A. Vince, Nicholas W. Eyrich, Brandon A. Mahal, Kristian Stensland, Edward M. Schaeffer, Daniel E. Spratt

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen

Nicholas W. Eyrich, John T. Wei, Yashar S. Niknafs, Javed Siddiqui, Chad Ellimoottil, Simpa S. Salami, Ganesh S. Palapattu, Rohit Mehra, Lakshmi P. Kunju, Scott A. Tomlins, Arul M. Chinnaiyan, Todd M. Morgan, Jeffrey J. Tosoian

Summary: This study aimed to evaluate the association between urinary MyProstateScore (MPS) and pathologic grade group in men diagnosed with GG1 prostate cancer. The results showed that MPS was significantly associated with the cancer grade at surgery, with a higher discriminative ability compared to models based on PSA and PSAD.

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)

Article Urology & Nephrology

Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need

Jeffrey J. Tosoian, Udit Singhal, Matthew S. Davenport, John T. Wei, Jeffrey S. Montgomery, Arvin K. George, Simpa S. Salami, Stanley G. Mukundi, Javed Siddiqui, Lakshmi P. Kunju, Benjamin P. Tooke, C. Yoonhee Ryder, Sarah P. Dugan, Zoey Chopra, Rachel Botbyl, Yilin Feng, Michael S. Sessine, Nicholas W. Eyrich, Ashley E. Ross, Bruce J. Trock, Scott A. Tomlins, Ganesh S. Palapattu, Arul M. Chinnaiyan, Yashar S. Niknafs, Todd M. Morgan

Summary: The study evaluated the complementary value of urinary MPS testing and mpMRI, finding that MPS is significantly associated with GG>2 cancer, especially performing better in the PIRADS 3 population.

UROLOGY (2021)

Article Urology & Nephrology

Virtual Matchmaking: Stakeholder Perspectives on the Future of the Urology Residency Match

Christopher J. Warren, Chanan R. Reitblat, Charles A. Ferreri, Nicholas W. Eyrich, Stephanie Daignault-Newton, Juan J. Andino, Hossein Sadeghi-Nejad, Raj S. Pruthi, Kate H. Kraft

Summary: This study examines stakeholders' perspectives on the lack of in-person externships and the transition to a virtual urology residency interview format. The majority of applicants were satisfied with their match outcomes, but unmatched applicants were significantly more likely to be unsatisfied. Most program directors expressed satisfaction with the match outcomes. Although most applicants and program directors recommended retaining an in-person externship option, there was ambivalence regarding the format of interviews for future match cycles.

UROLOGY (2022)

Editorial Material Urology & Nephrology

Assessing the Impact of Decision Aid Use on Post Prostatectomy Patient Reported Outcomes

Roberto A. Navarrete, Nicholas W. Eyrich, Kristian D. Stensland

UROLOGY (2022)

Article Urology & Nephrology

The Lack of a Physical Exam During New Patient Telehealth Visits Does Not Impact Plans for Office and Operating Room Procedures br

Nicholas W. Eyrich, Juan J. Andino, Roberta E. Ukavwe, Mark W. Farha, Akshar K. Patel, Daniel Triner, Chad Ellimoottil

Summary: The majority of surgical plans developed during new patient video visits remain unchanged after in-person evaluation. However, changes in clinical course or updated imaging can alter operative plans. Likewise, certain urologic conditions rely on the genitourinary examination to dictate surgical approach.

UROLOGY (2022)

Article Oncology

Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer

Andi K. Cani, Kevin Hu, Chia -Jen Liu, Javed Siddiqui, Yingye Zheng, Sumin Han, Srinivas Nallandhighal, Daniel H. Hovelson, Lanbo Xiao, Trinh Pham, Nicholas W. Eyrich, Heng Zheng, Randy Vince, Jeffrey J. Tosoian, Ganesh S. Palapattu, Todd M. Morgan, John T. Wei, Aaron M. Udager, Arul M. Chinnaiyan, Scott A. Tomlins, Simpa S. Salami

Summary: A novel urine-based RNA NGS assay can improve the early detection of aggressive prostate cancer by utilizing next-generation sequencing technology and combining multiple biomarkers including gene fusions, long non-coding RNAs, and mutations. The developed detection model outperforms current serum tests and sequencing-derived indexes in predicting aggressive prostate cancer through machine learning.

EUROPEAN UROLOGY ONCOLOGY (2022)

Article Oncology

Distinct Patterns of Clonal Evolution Drive Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia

Tiffany Guess, Chad R. Potts, Pawan Bhat, Justin A. Cartailler, Austin Brooks, Clinton Holt, Ashwini Yenamandra, Ferrin C. Wheeler, Michael R. Savona, Jean -Philippe Cartailler, P. Brent Ferrell

Summary: Precise clonal trajectories in MDS progression are uncovered using single-cell genomic sequencing. The study defines the patterns of clonal architecture and evolution driving the transformation to secondary AML. The phenotypic and transcriptional changes of disease progression are further characterized at the single-cell level.

BLOOD CANCER DISCOVERY (2022)

Article Oncology

Opioid prescribing exceeds consumption following common surgical oncology procedures

Nicholas W. Eyrich, Kenneth R. Sloss, Ryan A. Howard, Michael P. Klueh, Michael J. Englesbe, Jennifer F. Waljee, Chad M. Brummett, Michael S. Sabel, Lesly A. Dossett, Jay S. Lee

Summary: The study found that opioid prescribing exceeds consumption following common surgical oncology procedures. While most patients received education on taking opioids, few received instructions on proper disposal, leading to a high percentage of unused opioids.

JOURNAL OF SURGICAL ONCOLOGY (2021)

No Data Available